MEDBOT-B (02252) soared 5.16% during intraday trading on Friday, following the release of its audited financial results for the year ended December 31, 2025.

The company reported a 114.20% year-on-year surge in revenue to RMB 551.07 million, driven by the rapid commercialization of its core laparoscopic robot "Toumai." Overseas sales skyrocketed to more than five times the 2024 level, accounting for 73% of total revenue. The gross profit jumped 209.20% to RMB 266.62 million, with the gross margin expanding to 48% from 34% the previous year.

Furthermore, the net loss narrowed significantly by 60.70% to RMB 254.12 million, while the adjusted net loss fell 65.80%. The company also reported a sharp reduction in free cash outflow and achieved positive free cash flow in the second half of 2025. These robust financial metrics, alongside operational progress including growing global orders for its robotic systems, fueled positive investor sentiment during the session.